# First-in-human Evaluation of [18F]CETO

> **NCT05361083** · EARLY_PHASE1 · COMPLETED · sponsor: **Uppsala University** · enrollment: 20 (actual)

## Conditions studied

- Primary Aldosteronism Due to Aldosterone Producing Adenoma
- Primary Aldosteronism Due to Nodular Hyperplasia
- Adrenal Cushing Syndrome
- Non-Secretory Adrenal Adenoma
- Adrenocortical Carcinoma

## Interventions

- **DRUG:** F18CETO

## Key facts

- **NCT ID:** NCT05361083
- **Lead sponsor:** Uppsala University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2021-04-01
- **Final completion:** 2022-02-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361083, "First-in-human Evaluation of [18F]CETO". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05361083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*